Parabilis Medicines, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
PBLS Nasdaq 2830 parabilismed.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Parabilis Medicines, Inc.

Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027 - Oct 24th, 2026 3:02 pm
Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors - Oct 24th, 2026 6:45 am
Parabilis Medicines (PBLS) Stock May Trade At A Premium Despite Fresh Zolucatetide Trial Updates - Oct 20th, 2026 2:06 pm
Parabilis Medicines (PBLS) Could Be 39% Undervalued As Zolucatetide Trial Expands - Oct 20th, 2026 1:12 pm
What Does Parabilis Medicines (PBLS) Expanding Zolucatetide Into FAP Mean? - Oct 20th, 2026 12:17 pm
Parabilis Soars 13% on Upcoming ESMO Data for “First-in-Class” Desmoid Tumor Drug - Oct 19th, 2026 11:30 am
Parabilis Medicines to Present Updated Clinical Data for Zolucatetide in Patients with Desmoid Tumors at ESMO Congress 2026 - Oct 19th, 2026 5:00 am
Parabilis Medicines Initiates Dose-Ranging Clinical Study of Zolucatetide in Familial Adenomatous Polyposis - Oct 14th, 2026 5:00 am
Phanes Therapeutics to participate in Longwood Healthcare Leaders Boston CEO, November 2-3, 2026 - Oct 13th, 2026 7:02 am
Sixty Degree Capital Extends Its Track Record as Five Portfolio Companies Enter the Public Markets in 2026 - Sep 28th, 2026 8:00 am
MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors - Sep 23rd, 2026 6:00 am
Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference - Sep 1st, 2026 5:00 am
Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors - Aug 25th, 2026 5:00 am
Young startups miss out on biotech venture funding rebound, MassBio says - Aug 24th, 2026 6:01 pm
Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates - Aug 13th, 2026 5:00 am
Parabilis Medicines (PBLS) Stock Valuation After Recent 10% Single Day Decline - Jun 15th, 2026 3:14 pm
Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - Jun 11th, 2026 2:05 pm